Related Experiment Video
Updated: May 1, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
MicroRNAs as prognostic markers in ovarian cancer
Marta Llauradó1, Blanca Majem2, Tatiana Altadill2
1Faculty of Medicine, University of British Columbia, Vancouver, Canada; Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain.
Abstract:
Ovarian cancer (OC) is the most lethal gynecological malignancy among women. Over 70% of women with OC are diagnosed in advanced stages and most of these cases are incurable. Although most patients respond well to primary chemotherapy, tumors become resistant to treatment. Mechanisms of chemoresistance in cancer cells may be associated with mutational events and/or alterations of gene expression through epigenetic events. Although focusing on known genes has already yielded new information, previously unknown non-coding RNAs, such as microRNAs (miRNAs), also lead insight into the biology of chemoresistance. In this review we summarize the current evidence examining the role of miRNAs as biomarkers of response and survival to therapy in OC. Beside their clinical implications, we also discuss important differences between studies that may have limited their use as clinical biomarkers and suggest new approaches.
Insights
MicroRNAs (miRNAs) show promise as biomarkers for ovarian cancer (OC) treatment response and survival. Understanding miRNA roles and study variations is key to improving their clinical use in this lethal gynecological malignancy.
Area of Science:
- Gynecologic Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Ovarian cancer (OC) is a highly lethal gynecological malignancy, frequently diagnosed at advanced, incurable stages.
- Most patients initially respond to chemotherapy, but chemoresistance ultimately limits treatment efficacy.
- Chemoresistance mechanisms involve genetic mutations and epigenetic alterations, including the role of non-coding RNAs like microRNAs (miRNAs).
Purpose of the Study:
- To review current evidence on the role of miRNAs as biomarkers for therapy response and survival in ovarian cancer.
- To discuss clinical implications and limitations of current miRNA biomarker studies.
- To propose new approaches for utilizing miRNAs in OC clinical practice.
Main Methods:
- Comprehensive literature review of studies investigating miRNAs in ovarian cancer chemoresistance and patient outcomes.
- Analysis of existing data on miRNA expression and its correlation with treatment response and survival.
- Critical evaluation of methodological differences and potential biases in current research.
Main Results:
- MicroRNAs (miRNAs) are implicated in the mechanisms of ovarian cancer chemoresistance.
- Specific miRNAs show potential as predictive biomarkers for treatment response and patient survival.
- Significant heterogeneity exists across studies, impacting the reliability and clinical translation of miRNA biomarkers.
Conclusions:
- MicroRNAs represent a promising area for developing novel biomarkers in ovarian cancer.
- Addressing study variations and standardizing methodologies are crucial for advancing miRNA clinical utility.
- Further research and innovative approaches are needed to fully leverage miRNAs for personalized ovarian cancer therapy.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
01:22MicroRNAs